[go: up one dir, main page]

SI2763690T1 - Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke - Google Patents

Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke

Info

Publication number
SI2763690T1
SI2763690T1 SI201230454T SI201230454T SI2763690T1 SI 2763690 T1 SI2763690 T1 SI 2763690T1 SI 201230454 T SI201230454 T SI 201230454T SI 201230454 T SI201230454 T SI 201230454T SI 2763690 T1 SI2763690 T1 SI 2763690T1
Authority
SI
Slovenia
Prior art keywords
lixisenatide
stenosis
obstruction
treatment
duct system
Prior art date
Application number
SI201230454T
Other languages
English (en)
Inventor
Jens Stechl
Irene Nowotny
Claudia Pfeiffer
Jean-Louis Pinquier
Jerome Msihid
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of SI2763690T1 publication Critical patent/SI2763690T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201230454T 2011-10-04 2012-10-02 Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke SI2763690T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11183867 2011-10-04
EP12766695.6A EP2763690B1 (en) 2011-10-04 2012-10-02 Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
PCT/EP2012/069485 WO2013050379A1 (en) 2011-10-04 2012-10-02 Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system

Publications (1)

Publication Number Publication Date
SI2763690T1 true SI2763690T1 (sl) 2016-03-31

Family

ID=46963761

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230454T SI2763690T1 (sl) 2011-10-04 2012-10-02 Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke

Country Status (11)

Country Link
US (1) US20130096060A1 (sl)
EP (1) EP2763690B1 (sl)
CY (1) CY1117394T1 (sl)
DK (1) DK2763690T3 (sl)
ES (1) ES2562651T3 (sl)
HR (1) HRP20160171T1 (sl)
HU (1) HUE028568T2 (sl)
PL (1) PL2763690T3 (sl)
PT (1) PT2763690E (sl)
SI (1) SI2763690T1 (sl)
WO (1) WO2013050379A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
WO2015104310A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2022212271A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2038597A1 (en) * 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU4063697A (en) 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
KR20050083713A (ko) 2002-10-02 2005-08-26 질랜드 파마 에이/에스 안정화된 엑센딘-4 화합물
WO2007028394A2 (en) 2005-09-08 2007-03-15 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort

Also Published As

Publication number Publication date
EP2763690B1 (en) 2015-11-25
US20130096060A1 (en) 2013-04-18
PT2763690E (pt) 2016-03-23
HUE028568T2 (en) 2016-12-28
DK2763690T3 (en) 2016-02-15
CY1117394T1 (el) 2017-04-26
HRP20160171T1 (hr) 2016-03-11
EP2763690A1 (en) 2014-08-13
PL2763690T3 (pl) 2016-04-29
ES2562651T3 (es) 2016-03-07
WO2013050379A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
PL2763690T3 (pl) Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych
GB2485291B (en) Cannabidiol for use in the treatment of generalised and/or partial seizures
HK1175170A1 (en) Pyridine and pyrazine derivative for the treatment of cf cf
EP2613735A4 (en) DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES
IL227193B (en) Plant extracts for the treatment and prevention of inflammation
EP2486061A4 (en) COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
IL227762A0 (en) Devices and methods for the treatment of blood vessels in body cavities
PT2740489T (pt) Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
HK1180320A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd copd
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
RS56870B1 (sr) Pirolopirimidinski derivati za primenu u lečenju virusnih infekcija
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
EP2696874A4 (en) COMPOSITIONS AND METHODS USED TO TREAT NASAL CONDITIONS
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
EP2661434A4 (en) NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
EP2515939A4 (en) VIRUSES UNDER THE EFFECT OF LIGHT, SYSTEMS AND METHODS OF USE THEREOF
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
HK1202260A1 (en) Agent for preventing and or treating veisalgia
HK1250484A1 (zh) 用於治療胰腺炎的吉卡賓和衍生物
HUE045812T2 (hu) Eljárás és berendezés tárgyak kezelésére
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
HK1165724A1 (en) Albumin and/or mannitol for the treatment of nasal polyposis
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina